安藤 俊夫

Identification of a deletion mutant of DNA topoisomerasel cDNA from a camptothecin-resistant subline of human colon carcinoma cells 

Jpn. J. Cancer Research 91 551-559 2000年  

薬物による二次癌の発生機構 

癌と化学療法 特集「二次癌」(癌と化学療法) 36(13) 1988-1998 1999年  

Synthesis of novel antitumor dihydroxanthone derivatives with inhibitory against DNA topoisomerase (]G0002[) 

Bioorganic&Medicinal Chemistry Letters 9(18) 2653-2656 1999年  

Upregulation of Lewis enzyme(Fuc-T(]G0003[))and plasma-type alpha 1,3-fucosyltransferase(Fuc-T(]G0006[))expression determines the augmented expression of sialyl Lewis x antigen in non-small cell lung cancer 

Intern. J. Cancer 83 70-79 1999年  

Cloning, expression and characterization of a novel UDP-galactose : b-N-acetylglucosamineb1,3-galactosyltransferase(b3Gal-T5)responsible for synthesis of type 1 chain in colorectal and pancreatic epithelia and tumor cells derived derived therefrom 

J. Biol. Chem. 274(18) 12499-12507 1999年  

Retroviral expression of a mutant(Gly-533)human DNA topoisomerasel (]G0001[) cDNA confers a dominat form of camptothecin resistant 

Intern. J. Cancer 81(1) 134-140 1999年  

Bis(2,6-dioxopierazines), catalytic inhibitors of DNA topoisomerase (]G0002[), as molecular probes, cardioprotectors and antitumor drugs 

In : Alain Gouyette ed. Topoisomerases and Inhibitors : From Basic Research to Clinical Development. Special Issue of Biochimie 80 235-246 1998年  

Catalytic inhibitors of DNA Topoisomerase (]G0002[). In : Neil Osherof ed. DNA Topoisomerases and Topoisomerase-Targeted Drugs 

Biochim. Biophys. 1400 155-171 1998年  

Structures of topostins, DNA topoisomerase (]G0001[) inhibitors of bacterial origin 

Tetrahedron 54(12) 2683-2690 1998年  

DNAトポイソメラーゼ阻害剤 

癌と化学療法 特集「癌抑制蛋白質と制癌剤-その構造と機能-:IV.制癌剤」癌と化学療法社 1526-1535 1997年  

Recognition of supercoiled DNA by human DNA topoisomerase (]G0001[) : Relative contribution of specific and nonspecific interactions 

Molecular Biology 31 347-356 1997年  

Effect of ICRF-193, a catalytic inibitor of topoisomerase (]G0002[) on sister chromatid exchange 

Anti-Cancer Drugs 8 637-642 1997年  

Interaction of DNA topoisomerase (]G0002[) catalytic inhibitor ICRF-193, a bisdioxopiperazine derivative, with conxerved region(s) of eukaryotic but not prokaryotic enzyme 

Biochem. Pharmacol. 54 545-550 1997年  

DNA topoisomerase (]G0002[) as the cellular target of a novel antitumor agent ICRF-193, a bisdioxopiperazine derivative, in Xenopus egg extract 

Biochem. Biophys. Res. Commun. 235(3) 571-575 1997年  

ICRF-193, a catalytic inhibitor of DNA topoisomerase (]G0002[), delays the cell cycle progression from metaphase, but not from anaphase to the G1 phase in mammalian cells 

FEBS Lett. 406(3) 267-270 1997年  

The combination of different types of antitumor topoisomerase (]G0002[) inhibitors, ICRF-193 and tive and antagonistic effects on cell survival, VP-16, has additive and antagonistic effects on cell survival depending on treatment schodule 

Anticancer Res. 16 2735-2740 1996年